Could a new drug alter the fate of common medications?
NCT ID NCT07745439
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This Phase 1 trial in about 18 healthy adults tests whether taking NTQ5082 capsules changes how the body processes midazolam, a short-acting sedative used as a probe to measure liver enzyme activity. Participants receive midazolam alone and then alongside single and repeated doses of NTQ5082, with blood samples tracking drug levels. The goal is to see if NTQ5082 affects the breakdown of midazolam, which could inform how NTQ5082 interacts with other medicines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTQ5082 capsules and midazolam oral solution
- What this could lead to
- If NTQ5082 is shown to affect midazolam levels, it could guide safe dosing of NTQ5082 with other medications that rely on the same liver enzyme.
- What could go wrong
- This is an early-phase study in a small group of healthy volunteers, so results may not predict effects in patients or account for all real-world drug interactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION (DDI) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults